Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-21
    E.g., 2018-06-21

Articles

172632 items
1:15 PM, Jun 15, 2018  |  BC Week In Review | Company News  |  Other News

WuXi picks Massachusetts for first U.S. manufacturing site

WuXi Biologics Inc. (HKSE:2269) said it will invest $60 million to construct a biologics production facility in Worcester, Mass. The manufacturing site will be WuXi Biologics' first in the U.S., and 11th overall. The company plans...
1:15 PM, Jun 15, 2018  |  BC Week In Review | Clinical News  |  Regulatory

Sunovion's PD therapy NDA gets PDUFA date

Sunovion Pharmaceuticals Inc. said FDA accepted an NDA for apomorphine sublingual film (APL-130277) to treat "off" episodes in Parkinson's disease (PD). The PDUFA date is Jan. 29, 2019. Sunovion, a unit of Sumitomo Dainippon Pharma Co....
1:14 PM, Jun 15, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Eisai, Purdue's insomnia candidate does not impair driving in Phase I

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase I Study 106 showing that insomnia candidate lemborexant (E2006) given each night at bedtime met the primary endpoint of...
1:14 PM, Jun 15, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

ABL snags $65M in series C

ABL Bio Inc. (Seongnam, South Korea) raised $65 million on June 8 in a series C round led by new investors DS Asset Management, Alpen Route Asset Management, Quad Asset Management and Hana Financial Investment. ABL...
12:59 PM, Jun 15, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

After announced merger, TapImmune raises $70M

TapImmune (NASDAQ:TPIV) jumped $3.05 (51%) to $9 June 8 after it priced a $70 million private placement led by new investor New Enterprise Associates. The company is selling 17.5 million shares at $4. New investors...
12:59 PM, Jun 15, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Immunovia issues $37.3M in new shares

Diagnostic company Immunovia AB (SSE:IMMNOV) raised SEK324.4 million ($37.3 million) on June 8 in a new share issue of 2.2 million shares at SEK150. Investors included Swedbank Robur, Handelsbanken Fonder, Alfred Berg Kapitalförvaltning, Nyenburgh Investment...
12:59 PM, Jun 15, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

ICER panel says long-term value for Aimovig for migraines is intermediate

ICER's California Technology Assessment Forum (CTAF) voted that the long-term value of calcitonin gene-related peptide (CGRP) inhibitor Aimovig erenumab for patients with chronic migraine who had previously failed other preventative migraine treatments was intermediate, while...
12:59 PM, Jun 15, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

ICER offers policy recommendations in final report for cystic fibrosis drugs

ICER released its final evidence report June 7 on CF transmembrane conductance regulator (CFTR) therapies that found that while Kalydeco ivacaftor, Orkambi ivacaftor/lumacaftor and Symdeko tezacaftor/ivacaftor offered a net benefit compared with supportive care alone,...
12:59 PM, Jun 15, 2018  |  BC Week In Review | Company News  |  Deals

Broad, Editas in research funding deal

Editas Medicine Inc. (NASDAQ:EDIT) and the Broad Institute of MIT and Harvard entered into a sponsored research agreement in which the gene editing company will provide funding for the institute to "conduct research useful or...
12:58 PM, Jun 15, 2018  |  BC Week In Review | Company News  |  Deals

Wuxi to use Insilico's AI platform to speed drug discovery

WuXi AppTec Co. Ltd. (Shanghai:603259) led a venture round for Insilico Medicine Inc. (Baltimore, Md.) and partnered with the artificial intelligence company to discover and develop new molecules. Insilico CEO Alex Zhavoronkov told BioCentury it raised...

Pages